Co-Chairs:
David S. Goldstein, NINDS and Huaibin Cai, NIA
Natcher Conference Center - Conference Room
E1/E2
Parkinson’s disease (PD) is the most common movement
disorder, affecting millions of people around the world. For the
past decade, major advances have been made in identifying genetic
factors associated with PD. The following biochemical, cell biology,
and animal modeling studies of these genetic mutations have begun
to reveal the molecular cascades leading to the dysfunction of
nigrostriatal system in PD and define therapeutic targets for potential
treatment. However, by the time the patient develops symptoms of
PD, the majority of dopaminergic terminals in the nigrostriatal
system has already been loss. Thus, much of the recent research
focus has also been on identifying early markers of PD, which may
then be applied to detect the disease in an early or even pre-symptomatic
phase. These two lines of research share the ultimate aim of PD
research, which is to gain an understanding of pathogenesis of
PD and to find more effective treatment or even prevention of the
disease.
Program:
Dopaminergic and Cardiac Sympathetic
Neuroimaging for Identifying Early Markers of PD
David S. Goldstein, NINDS
The Genetics of PD
Andrew Singleton, NIA
Novel Genetically Engineered Mouse
Models of PD
Dr. Huaibin Cai, NIA
Gaucher Disease and the Synucleinopathies
Dr. Ellen Sidransky, NHGRI |